Literature DB >> 6446433

Suppressor cell activity in viral and non-viral chronic active hepatitis.

F Tremolada, G Fattovich, G Panebianco, G Ongaro, G Realdi.   

Abstract

Suppressor cell function was studied in twenty-nine patients with chronic active hepatitis (CAH) in relation to possible aetiological causes and activity of liver disease. All fifteen patients with evidence of viral aetiology (ten HBsAg-positive CAH and five non-A, non-B CAH) showed normal suppressor cell function independently of severity of liver damage. In contrast, fourteen patients with HBsAg-negative CAH, including four cases with circulating antibodies to the hepatitis B virus, demonstrated a significant reduction in supprpessor cell activity compared to control subjects. No significant difference was found in this group between cases with and without circulating autoantibodies. In four out of five HBsAg-negative patients tested serially suppressor cell defect correlated with disease activity suggesting an abnormality in the regulation rather than a depletion of suppressor cells. These results suggest that different mechanisms are responsible for autoimmunity to the liver in virus and non-virus-related CAH.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6446433      PMCID: PMC1536957     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  10 in total

1.  In vitro studies of suppressor cell function in human peripheral blood mononuclear cells.

Authors:  C Feighery; C A Whelan; D G Weir; J F Greally
Journal:  Clin Exp Immunol       Date:  1978-06       Impact factor: 4.330

2.  Decreased suppressor cell activity in inflammatory bowel disease.

Authors:  H J Hodgson; J R Wands; K J Isselbacher
Journal:  Clin Exp Immunol       Date:  1978-06       Impact factor: 4.330

3.  Alteration in suppressor cell activity in chronic active hepatitis.

Authors:  H J Hodgson; J R Wands; K J Isselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

Review 4.  Cooperating and controlling functions of thymus-derived lymphocytes in relation to autoimmunity.

Authors:  A C Allison; A M Denman; R D Barnes
Journal:  Lancet       Date:  1971-07-17       Impact factor: 79.321

5.  A classification of chronic hepatitis.

Authors:  J De Groote; V J Desmet; P Gedigk; G Korb; H Popper; H Poulsen; P J Scheuer; M Schmid; H Thaler; E Uehlinger
Journal:  Lancet       Date:  1968-09-14       Impact factor: 79.321

6.  Suppressor T cell function in diabetes mellitus.

Authors:  S D Horowitz; W Borcherding; G J Bargman
Journal:  Lancet       Date:  1977-12-17       Impact factor: 79.321

7.  Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis.

Authors:  A L Eddleston; R Williams
Journal:  Lancet       Date:  1974-12-28       Impact factor: 79.321

8.  Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus.

Authors:  B Bresnihan; H E Jasin
Journal:  J Clin Invest       Date:  1977-01       Impact factor: 14.808

9.  Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis.

Authors:  D M Jensen; I G McFarlane; B S Portmann; A L Eddleston; R Williams
Journal:  N Engl J Med       Date:  1978-07-06       Impact factor: 91.245

Review 10.  Hepatitis-associated antigen.

Authors:  N R Shulman
Journal:  Am J Med       Date:  1970-11       Impact factor: 4.965

  10 in total
  15 in total

1.  In-vitro cell-mediated cytotoxicity for autologous liver cells in chronic non-A, non-B hepatitis.

Authors:  M Mondelli; A Alberti; F Tremolada; R Williams; A L Eddleston; G Realdi
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

2.  Effect of neonatal thymectomy on experimental autoimmune hepatitis in mice.

Authors:  Y Watanabe; H Kawakami; H Kawamoto; Y Ikemoto; K Masuda; E Takezaki; T Nakanishi; G Kajiyama; H Takeno
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

3.  Humoral and cellular immune responses by normal individuals to hepatitis B surface antigen vaccination.

Authors:  L G Filion; R Saginur; N Szczerbak
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

4.  Remission of experimental autoimmune hepatitis is associated with antigen-specific and non-specific immunosuppression.

Authors:  A W Lohse; K H Meyer zum Büschenfelde
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

5.  Regulatory T cell-subset imbalance in chronic active hepatitis.

Authors:  G Carella; L Chatenoud; F Degos; M A Bach
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

6.  B cell activation by pokeweed mitogen in cultures of normal peripheral blood lymphocytes depleted of T regulator subsets by treatment with OKT4 and OKT8 monoclonal antibodies.

Authors:  B M Jones
Journal:  Clin Exp Immunol       Date:  1983-03       Impact factor: 4.330

7.  Increased thymic hormone responsive suppressor T lymphocyte function in chronic active hepatitis.

Authors:  M G Mutchnick; J A Schaffner; J A Prieto; F E Weller; A L Goldstein
Journal:  Dig Dis Sci       Date:  1983-04       Impact factor: 3.199

8.  Peripheral blood mononuclear cells and regulatory T cells in acute viral hepatitis.

Authors:  V Barnaba; E Tamburrini; V Laghi; R Cauda; M Levrero; G Ruocco; L Ortona; F Balsano
Journal:  Gut       Date:  1985-07       Impact factor: 23.059

9.  Enhanced clonability of human T lymphocytes caused by their culturing in vitro.

Authors:  A Górski; Z Gaciong; B Dupont
Journal:  Immunology       Date:  1981-11       Impact factor: 7.397

10.  Cellular and humoral immune reactions in chronic active liver disease. I. Lymphocyte subsets in liver biopsies of patients with untreated idiopathic autoimmune hepatitis, chronic active hepatitis B and primary biliary cirrhosis.

Authors:  H F Eggink; H J Houthoff; S Huitema; C H Gips; S Poppema
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.